TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04389073
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT03064074
Drug: Fresolimumab
Normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
Study: NCT00413439
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution or oral capsules
Study: NCT03767257
Drug: Colesevelam Pill
Normalized name: colesevelam Pill
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
Study: NCT01951053
Drug: JNJ-40411813
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
Study: NCT01951053
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
Study: NCT03083782
Drug: Apixaban alone
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of 10 mg apixaban administered orally at 0H on Day 1.
Study: NCT03083782
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
Study: NCT03083782
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
Study: NCT03083782
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
Study: NCT03083782
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
Study: NCT01278264
Drug: Ropivacaine 0.25%, 0.5 ml/kg
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
Study: NCT01278264
Drug: Ropivacaine 0.25%, 0.5 ml/kg
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
Study: NCT02539550
Drug: PF-06266047
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06266047
Study: NCT03950232
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
Study: NCT02332473
Drug: Ypeginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02332473
Drug: Granulocyte-macrophage colony stimulating factor
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00499525
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given IV
Study: NCT00499525
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orallly
Study: NCT02526784
Drug: degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05236166
Drug: Rapid withdrawal of antiepileptic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Study: NCT05236166
Drug: Slow withdrawal of antiepileptic
Normalized name: Slow-Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Study: NCT00131521
Drug: mucomyst
Normalized name: Mucomyst
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131521
Drug: sodium chloride (saline)
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03394989
Drug: Fluticasone propionate/salmeterol 100/50 µg
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Test Arm: Dry powder inhaler
Study: NCT00407719
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00951392
Drug: euglycemic hyperinsulinemic clamp
Normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests
Study: NCT00677794
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids only after lunch.
Study: NCT00677794
Drug: Picosalax
Normalized name: picosulfate sodium Oral Solution [Picolax]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two sachets the evening prior to Video Capsule Endoscopy (VCE).
Study: NCT00677794
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
Study: NCT02361892
Drug: ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
Study: NCT03634956
Drug: Group B. Sugammadex sodium-IONM
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
Study: NCT04255771
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
Study: NCT03997864
Drug: Prazosin
Normalized name: Prazosin
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks.
Study: NCT00691392
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
Study: NCT00691392
Drug: Microcrystalline Methylcellulose - Placebo
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be over-encapsulated microcrystalline methylcellulose
Study: NCT04289779
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib 40 mg orally daily for 3 cycles
Study: NCT04289779
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
Study: NCT00735774
Drug: 11C-ORM-13070
Normalized name: 11C-ORM-13070
DrugBank: ORM-13070 C-11 (DB15324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of i.v. solution
Study: NCT03695887
Drug: Nitrous Oxide Inhalant Product
Normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous Oxide Inhalant Product
Study: NCT01928433
Drug: Finafloxacin 800 mg i.v. once daily
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Study: NCT01928433
Drug: Finafloxacin placebo i.v. once daily
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Study: NCT01928433
Drug: Finafloxacin 800 mg tablets once daily
Normalized name: eslicarbazepine
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as four 200 mg tablets
Study: NCT01928433
Drug: Finafloxacin placebo tablets once daily
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as four tablets
Study: NCT01928433
Drug: Ciprofloxacin 400 mg i.v. twice daily
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Study: NCT01928433
Drug: Ciprofloxacin placebo i.v. twice daily
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Study: NCT01928433
Drug: Ciprofloxacin 500 mg oral twice daily
Normalized name: deferiprone
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as two 250 mg capsules.
Study: NCT01928433
Drug: Ciprofloxacin placebo oral twice daily
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as two capsules.
Study: NCT01624714
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
Study: NCT01624714
Drug: Alemtuzumab immunotherapy
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
Study: NCT01876212
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03189732
Drug: Metformin Oral
Normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03189732
Drug: Metformin local in AT
Normalized name: AT-7519
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01913327
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01913327
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
Study: NCT01913327
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
Study: NCT00575913
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfuzosin 10 mg One tablet per day after evening meal
Study: NCT01132482
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
Study: NCT01010906
Drug: Vaniprevir 300 mg
Normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: single dose administration of 300 mg oral tablet
Study: NCT01010906
Drug: Vaniprevir 200 mg
Normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: single dose administration of 200 mg oral tablet
Study: NCT03928847
Drug: Epigallocatechin-3-gallate (EGCG)
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin-3-gallate (EGCG) capsules
Study: NCT01763424
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Study: NCT03725007
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.
Study: NCT00048295
Drug: Alicaforsen
Normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04409834
Drug: Enoxaparin 1 mg/kg
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
Study: NCT04409834
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
Study: NCT04409834
Drug: Enoxaparin 40 mg SC
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
Study: NCT03341676
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 3.3 mg/mL solution for injection
Study: NCT00003156
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03829592
Drug: misoprostol in a neutral media
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving misoprostol in a neutral media
Study: NCT03829592
Drug: misoprostol in an acidic media
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving misoprostol in an acidic media
Study: NCT03829592
Drug: misoprostol in an alkaline media
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving misoprostol in an alkaline media
Study: NCT00769054
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Infiltration Analgesia with 1 % Ropivacaine
Study: NCT02292537
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intrathecal (IT) lumbar puncture (LP) injection
Study: NCT04096417
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01400009
Drug: Vitamin D (Cholecalciferol )
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
Study: NCT04055753
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxil 50 mg/m2, as per institutional standard
Study: NCT02296476
Drug: Birabresib
Normalized name: Birabresib
DrugBank: Birabresib (DB15189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally in a fasted state once daily.
Study: NCT00445094
Drug: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00445094
Drug: Comparator: vancomycin / Duration of Treatment: 3 Days
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02722408
Drug: Gemcabene
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
Study: NCT03344341
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
Study: NCT03344341
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
Study: NCT03313414
Drug: Sofosbuvir/Velpatasvir Treatment for 14 days
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14 day therapy with Sofosbuvir/Velpatasvir
Study: NCT00563758
Drug: tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457392
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Study: NCT03790839
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin (Januvia® 100 mg tablets for oral administration)
Study: NCT00457392
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
Study: NCT03991910
Drug: Ramipril 5Mg Oral Capsule
Normalized name: Ramipril 5mg Oral capsule
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
Study: NCT04485845
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
Study: NCT04485845
Drug: Captopril Tablets
Normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector
Study: NCT04485845
Drug: MetFORMIN 500 Mg Oral Tablet
Normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
Study: NCT03790839
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucokinase activator currently under development
Study: NCT04352855
Drug: Ceftolozane/tazobactam
Normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration
Study: NCT00696033
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazépam drug (0,3 mg/kg) on a single oral intake
Study: NCT00696033
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazépam drug (0,038 mg/kg) on a single oral intake